PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMosunetuzumab
Lunsumio(mosunetuzumab)
Lunsumio (mosunetuzumab) is an antibody pharmaceutical. Mosunetuzumab was first approved as Lunsumio on 2022-06-03. It is used to treat follicular lymphoma in the USA. It has been approved in Europe to treat follicular lymphoma. It is known to target B-lymphocyte antigen CD20.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Lunsumio
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Mosunetuzumab
Tradename
Proper name
Company
Number
Date
Products
Lunsumiomosunetuzumab-axgbGenentechN-761263 RX2022-12-22
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
lunsumioBiologic Licensing Application2024-12-04
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
follicular lymphoma—D008224C82
Agency Specific
FDA
EMA
Expiration
Code
mosunetuzumab, Lunsumio, Genentech, Inc.
2029-12-22Orphan excl.
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
46 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMosunetuzumab
INNmosunetuzumab
Description
Mosunetuzumab, sold under the brand name Lunsumio, is a monoclonal antibody used for the treatment of follicular lymphoma. It bispecifically binds CD20 and CD3 to engage T-cells. It was developed by Genentech.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1905409-39-3
RxCUI—
ChEMBL IDCHEMBL4297788
ChEBI ID—
PubChem CID—
DrugBankDB15434
UNII IDLDJ89SS0YG (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
MS4A1
MS4A1
Organism
Homo sapiens
Gene name
MS4A1
Gene synonyms
CD20
NCBI Gene ID
931
Protein name
B-lymphocyte antigen CD20
Protein synonyms
B-lymphocyte cell-surface antigen B1, B-lymphocyte surface antigen B1, Bp35, CD20, CD20 antigen, CD20 receptor, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, membrane-spanning 4-domains, subfamily A, member 1
Uniprot ID
Q13963
Mouse ortholog
Ms4a1 (12482)
B-lymphocyte antigen CD20 (P19437)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 693 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lunsumio
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
620 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use